The FDA announced on Friday that Merck's anti-baldness and prostate drug finasteride, sold under the names Propecia and Proscar, will now carry new warning labels. Both labels of the drug will now warn users of possible sexual side effects including libido disorders, ejaculation disorders, and orgasm disorders.
According to CBSnews.com, the FDA fielded 421 reports of sexual side effects through their Adverse Events Reporting System for Propecia and another 131 for Proscar.
"Despite the fact that clear causal links between finasteride (Propecia and Proscar) and sexual adverse events have NOT been established, the cases suggest a broader range of adverse effects than previously reported in patients taking these drugs," the FDA said in a statement.
"Therefore, prescribers and patients need to be aware of them, as part of a discussion of risk and benefits of finasteride when determining the best treatment options."
For comments and feedback contact: editorial@rttnews.com
Health News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.